233 related articles for article (PubMed ID: 15029092)
1. Clinical interest of PPARs ligands.
Vergès B
Diabetes Metab; 2004 Feb; 30(1):7-12. PubMed ID: 15029092
[TBL] [Abstract][Full Text] [Related]
2. Metabolic and additional vascular effects of thiazolidinediones.
Martens FM; Visseren FL; Lemay J; de Koning EJ; Rabelink TJ
Drugs; 2002; 62(10):1463-80. PubMed ID: 12093315
[TBL] [Abstract][Full Text] [Related]
3. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors with functions in the vascular wall.
Chinetti G; Fruchart JC; Staels B
Z Kardiol; 2001; 90 Suppl 3():125-32. PubMed ID: 11374025
[TBL] [Abstract][Full Text] [Related]
4. [Pharmacology of PPARalpha, PPARgamma and dual PPARalpha/gamma agonists in clinical development].
Duran-Sandoval D; Thomas AC; Bailleul B; Fruchart JC; Staels B
Med Sci (Paris); 2003; 19(8-9):819-25. PubMed ID: 14593612
[TBL] [Abstract][Full Text] [Related]
5. PPARS in inflammation, atherosclerosis and thrombosis.
Duez H; Fruchart JC; Staels B
J Cardiovasc Risk; 2001 Aug; 8(4):187-94. PubMed ID: 11550996
[TBL] [Abstract][Full Text] [Related]
6. Inflammation, dyslipidaemia, diabetes and PPars: pharmacological interest of dual PPARalpha and PPARgamma agonists.
Gervois P; Fruchart JC; Staels B
Int J Clin Pract Suppl; 2004 Oct; (143):22-9. PubMed ID: 16035393
[TBL] [Abstract][Full Text] [Related]
7. [New concepts on the mechanism of action of fibrates and therapeutic prospectives in atherosclerosis].
Fruchart JC; Staels B; Duriez P
Bull Acad Natl Med; 2001; 185(1):63-74; discussion 74-5. PubMed ID: 11474570
[TBL] [Abstract][Full Text] [Related]
8. Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis.
Fruchart JC; Duriez P; Staels B
Curr Opin Lipidol; 1999 Jun; 10(3):245-57. PubMed ID: 10431661
[TBL] [Abstract][Full Text] [Related]
9. Insulin resistance and its treatment by thiazolidinediones.
Lebovitz HE; Banerji MA
Recent Prog Horm Res; 2001; 56():265-94. PubMed ID: 11237217
[TBL] [Abstract][Full Text] [Related]
10. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation.
Chinetti G; Fruchart JC; Staels B
Inflamm Res; 2000 Oct; 49(10):497-505. PubMed ID: 11089900
[TBL] [Abstract][Full Text] [Related]
11. [Role of the peroxisome proliferator-activated receptors (PPARS) in the regulation of lipids and inflammation control].
Bocher V; Chinetti G; Fruchart JC; Staels B
J Soc Biol; 2002; 196(1):47-52. PubMed ID: 12134632
[TBL] [Abstract][Full Text] [Related]
12. PPARS, insulin resistance and type 2 diabetes.
Kaplan F; Al-Majali K; Betteridge DJ
J Cardiovasc Risk; 2001 Aug; 8(4):211-7. PubMed ID: 11550999
[TBL] [Abstract][Full Text] [Related]
13. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells.
Marx N; Duez H; Fruchart JC; Staels B
Circ Res; 2004 May; 94(9):1168-78. PubMed ID: 15142970
[TBL] [Abstract][Full Text] [Related]
14. Modulation of vascular inflammation by PPARs.
Tham DM; Wang YX; Rutledge JC
Drug News Perspect; 2003 Mar; 16(2):109-16. PubMed ID: 12792672
[TBL] [Abstract][Full Text] [Related]
15. A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models.
Etgen GJ; Oldham BA; Johnson WT; Broderick CL; Montrose CR; Brozinick JT; Misener EA; Bean JS; Bensch WR; Brooks DA; Shuker AJ; Rito CJ; McCarthy JR; Ardecky RJ; Tyhonas JS; Dana SL; Bilakovics JM; Paterniti JR; Ogilvie KM; Liu S; Kauffman RF
Diabetes; 2002 Apr; 51(4):1083-7. PubMed ID: 11916929
[TBL] [Abstract][Full Text] [Related]
16. Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis.
Barbier O; Torra IP; Duguay Y; Blanquart C; Fruchart JC; Glineur C; Staels B
Arterioscler Thromb Vasc Biol; 2002 May; 22(5):717-26. PubMed ID: 12006382
[TBL] [Abstract][Full Text] [Related]
17. Experimental approaches to study PPAR gamma agonists as antidiabetic drugs.
Vázquez M; Silvestre JS; Prous JR
Methods Find Exp Clin Pharmacol; 2002 Oct; 24(8):515-23. PubMed ID: 12500431
[TBL] [Abstract][Full Text] [Related]
18. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
Touyz RM; Schiffrin EL
Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
[TBL] [Abstract][Full Text] [Related]
19. PPAR Agonists and Metabolic Syndrome: An Established Role?
Botta M; Audano M; Sahebkar A; Sirtori CR; Mitro N; Ruscica M
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29662003
[TBL] [Abstract][Full Text] [Related]
20. Diabetic dyslipidaemia: insights for optimizing patient management.
Vergès B
Curr Med Res Opin; 2005; 21 Suppl 1():S29-40. PubMed ID: 15811197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
